Skip to main content

Currently Skimming:


Pages 138-148

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 138...
... To inform their future priorities for the smallpox MCM portfolio, BARDA and PHEMCE could develop new TPPs and refine existing TPPs for smallpox MCMs. This could include defining the product, including both the indication (i.e., disease/condition to be treated)
From page 139...
... • Examine the potential uses of and implications for currently stockpiled MCMs for other orthopoxvirus outbreaks. Consider the threat of other orthopoxvi ruses that stockpiled smallpox MCMs could be used for, and furthermore, if mpox becomes a more serious global health problem, consider the risk of further depletion of stockpiled smallpox MCMs.
From page 140...
...  Should sustaining stores of smallpox vaccines be viewed as an irrevocable obligation while purchases of other products for the SNS are discretion ary? And what is a reasonable price to pay for new vaccine doses to replace expiring doses?
From page 141...
... Based on the evidence and findings on the utility of live variola virus for research and the smallpox MCM portfolio planning, the committee drew the following overarching conclusions: For the foreseeable future, some research with live variola virus remains essential to achieving public health research goals against an ever evolving biothreat landscape and the potential for orthopoxviruses to emerge naturally or deliberately. The smallpox MCM portfolio is a mature portfolio, and the goals of a mature portfolio should differ from a relatively new MCM portfolio.
From page 142...
... 2023. Strategic National Stockpile​smallpox medical countermeasures​overview​.
From page 143...
... 2023. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge.
From page 144...
... 2021. The Strategic National Stockpile: Identification, support, and acquisition of medical countermeasures for CBRN incidents.
From page 145...
... 2023. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus.
From page 146...
... 2023. Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge.
From page 147...
... convened the Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures. In addressing its charge and preparing its final report, the committee pursued several avenues for information collection and analysis.
From page 148...
... 2:00 p.m. Welcoming Remarks LARRY GOSTIN, Committee Chair Distinguished University Professor and O'Neill Chair in Global Health Law O'Neill Institute for National and Global Health Law Georgetown University 2:05 p.m.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.